Table 2 Study and Participant Characteristics

Avila et al. [67]

Belgium

30 c 60 i 84^a

3/27 c 4/26 i

61.7 ± 7.7 c 58.6 ± 13 i

CAD, MI, CABG, PCI

86.67 c 93.33 i

Butler et al. [68]

Australia

60 c, 62 i 6/52: 50 c, 48 i; 98^a 6/12: 46 c, 44 I; 90^a

10/45 c 17/38 i

64.5 ± 11.2 c 63 ± 10.4 i

MI, CABG, PCI, ACS

6/52: 90.9 c; 87.3 i 6/12: 83.64 c; 80 i

Cupples et al. [69]

Northern Ireland

26 c 19 i

1/25 c 3/16 i

59.2 ± 8.9 c 61.6 ± 11.3 i

Not published

96 c 90 i

Duscha et al. [70]

America

11 c 21 i; 25^a

3/6 c 3/13 i

66.5 ± 7.2 c 59.9 ± 8.1 i

MI with PCI or CABG, PCI, CABG, VR

81.8 c 76.2 i

Guiraud et al. [71]

France

10 c 19 i

3/7 c 2/17 i

62.9 ± 10.7 c 54.5 ± 12.6 i

CAD, CABG, PCI, HF

100 c 100 i

Houle et al. [72]

Canada

33 c 32 i

8/25 c 6/26 i

59 ± 9 c 58 ± 8 i

MI, CABG, PCI, UA

Data not published

Skobel et al. [73]

Germany, Spain, Britain

63 c 55 i 54^a:42 c,12 i

8/55 c 5/ 50 i

58 c* 60 i*

MI, PCI

66.7 c, 21.8 i

ter Hoeve et al. [52]

Netherlands

163 c 161 i

32/131 c 32/129 i

59.1 ± 8 c 58.8 ± 9 i

MI, CABG, PCI, ACS

3/12: 78 c, 80.1 i 12/12: 75 c,75 i 18/12: 74.7 c,74.8 i

Varnfield et al. [53]

Australia

41 c 53 i 6/52:28 c 48 i; 76^a 6/12: 26 c, 46 i; 72^a

7/34 c 5/48 i

56.2 ± 10.1 c 54.9 ± 9.6 i

MY

6/52:46.7 c, 80 i 6/12:43.3 c,76.7 i